Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.
A patient presents with sudden-onset right-sided otalgia accompanied by vertigo, emesis, and auditory impairment. Your otoscope reveals an unexpected finding. What's your diagnosis?